Research Topics
| Ciska BuijsSummaryAffiliation: University Medical Center Groningen Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
The influence of endocrine treatments for breast cancer on health-related quality of lifeCiska Buijs
Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, P O Box 30001, 9700 RB Groningen, The Netherlands
Cancer Treat Rev 34:640-55. 2008..HRQoL during progestins and the SERM fulvestrant has been compared to this during aromatase inhibitors, and a large number of studies on HRQoL during endocrine therapy will be discussed...
Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over studyCiska Buijs
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Breast Cancer Res Treat 115:573-80. 2009..We compared venlafaxine and clonidine for the treatment of HF with regard to side effects, efficacy, quality of life and sexual functioning...
Effect of tamoxifen on the endometrium and the menstrual cycle of premenopausal breast cancer patientsCiska Buijs
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, The Netherlands
Int J Gynecol Cancer 19:677-81. 2009..This study aimed to investigate the influence of tamoxifen on the menstrual cycle and serum hormone levels and the subsequent endometrial response in premenopausal breast cancer patients...
Hot flushes in breast cancer patientsConstantijne H Mom
Department of Medical Oncology, University Medical Center, P.O. Box 30001, 9700 RB Groningen, The Netherlands
Crit Rev Oncol Hematol 57:63-77. 2006..However, studies on interaction between SSRIs and tamoxifen may influence future recommendations...
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal studyPeter Nieboer
University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
J Clin Oncol 23:8296-304. 2005..CONCLUSION: In 3 years after treatment, no significant differences in fatigue were found between standard and high-dose chemotherapy. Fatigue did not change over time. The strongest fatigue predictor was poor mental health...
